Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$761,000Cash on Hand
1.3mo Cash Runway
Follow MTNB by emailGet an email when MTNB pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about MTNB, unsubscribe in one click. Privacy
🧪 Trial & FDA Catalysts
Nov 2022 · Phase 1/2 · Results Expected · Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT) Registry primary completion date, not a results date
Nov 2021 · Phase 2 · Results Expected · CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis Registry primary completion date, not a results date
Nov 2020 · Phase 2 · Results Expected · Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adu Registry primary completion date, not a results date
May 2017 · Phase 2 · Results Expected · Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Registry primary completion date, not a results date
May 2015 · Phase 1/2 · Results Expected · A PK and PD Study of Two Formulations of Omega-3 One Gram Capsules Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not MTNB's own candidates): Amphotericin B, Fluconazole, Icosapent Ethyl.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
MTNB holds $761,000 in cash and short-term investments (as of Jun 30, 2026) and burns about $1.7M/quarter from operations,
an estimated runway of 1.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:50 · Elevated
Cash runway 1 months +40
Share count +189% in a year +20
Raised after last reported balance sheet (Jul 2026) -10
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MTNB and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.